Development and Optimization of Eudragit® EPO Coated Solid Dispersion-Based Immediate-Release Pellets of Drotaverine Hydrochloride for Pediatric use

The study aimed to develop a pediatric-friendly, immediate-release pellet formulation of Drotaverine Hydrochloride (DHC) to address issues related to poor aqueous solubility, bitter taste, and dosing flexibility in children. The objective was to enhance solubility and ensure rapid drug release while masking the bitter taste of drug. Solid dispersions of DHC were prepared using Polyethylene Glycol (PEG) 4000 and PEG 6000 via the solvent evaporation technique. These were converted into pellets using extrusion–spheronization, with MCC (Microcrystalline Cellulose), as the pelletizing agent and Eudragit® EPO coating for taste masking. A 2³ factorial design was employed to optimize critical variables: spheronization speed, PEG type, and superdisintegrant concentration. The optimized batch was evaluated for physicochemical properties, disintegration, drug content, in vitro drug release in both gastric and oral pH, and kinetic modeling. The optimized formulation (DHP6) comprised a solid dispersion of DHC with PEG 4000 (1:2 ratio), 10% superdisintegrant, and a spheronization speed of 7000 rpm. It exhibited a pellet size of 0.78 ± 0.02 mm, t85 of 15 ± 3.25 min, and disintegration time of 0.83 ± 0.04 min. The pellets showed excellent flowability (angle of repose: 12.04°; Hausner ratio: 1.01), friability (0.12 ± 0.004%), and acceptable hardness (0.55 ± 0.25 g/cm²). In vitro release studies demonstrated > 85% drug release within 15 min in 0.1 N HCl and negligible release in simulated salivary fluid, confirming effective taste masking. Release kinetics followed the Korsmeyer-Peppas model (R² = 0.9862), indicating diffusion-controlled release. The developed immediate-release pellets of DHC offer improved solubility, rapid gastric release, and effective taste masking, making them a promising pediatric dosage form for abdominal pain management. The optimized formulation (DHP6) demonstrated robust physicochemical and performance characteristics, supporting its potential for pediatric use.

Authors

Institutions

Publication Details

Journal
Journal of Pharmaceutical Innovation
Published
2025-09-16
DOI
https://doi.org/10.1007/s12247-025-10080-x
Primary Topic
Pharmaceutical studies and practices
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Development and Optimization of Eudragit® EPO Coated Solid Dispersion-Based Immediate-Release Pellets of Drotaverine Hydrochloride for Pediatric use

Meenakshi Patel, Mitali Upadhyay, H. Patel
Journal of Pharmaceutical Innovation
Pharmaceutical studies and practices
article

Development and Optimization of Eudragit® EPO Coated Solid Dispersion-Based Immediate-Release Pellets of Drotaverine Hydrochloride for Pediatric use

Meenakshi Patel, Mitali Upadhyay, H. Patel
article en

Abstract

The study aimed to develop a pediatric-friendly, immediate-release pellet formulation of Drotaverine Hydrochloride (DHC) to address issues related to poor aqueous solubility, bitter taste, and dosing flexibility in children. The objective was to enhance solubility and ensure rapid drug release while masking the bitter taste of drug. Solid dispersions of DHC were prepared using Polyethylene Glycol (PEG) 4000 and PEG 6000 via the solvent evaporation technique. These were converted into pellets using extrusion–spheronization, with MCC (Microcrystalline Cellulose), as the pelletizing agent and Eudragit® EPO coating for taste masking. A 2³ factorial design was employed to optimize critical variables: spheronization speed, PEG type, and superdisintegrant concentration. The optimized batch was evaluated for physicochemical properties, disintegration, drug content, in vitro drug release in both gastric and oral pH, and kinetic modeling. The optimized formulation (DHP6) comprised a solid dispersion of DHC with PEG 4000 (1:2 ratio), 10% superdisintegrant, and a spheronization speed of 7000 rpm. It exhibited a pellet size of 0.78 ± 0.02 mm, t85 of 15 ± 3.25 min, and disintegration time of 0.83 ± 0.04 min. The pellets showed excellent flowability (angle of repose: 12.04°; Hausner ratio: 1.01), friability (0.12 ± 0.004%), and acceptable hardness (0.55 ± 0.25 g/cm²). In vitro release studies demonstrated > 85% drug release within 15 min in 0.1 N HCl and negligible release in simulated salivary fluid, confirming effective taste masking. Release kinetics followed the Korsmeyer-Peppas model (R² = 0.9862), indicating diffusion-controlled release. The developed immediate-release pellets of DHC offer improved solubility, rapid gastric release, and effective taste masking, making them a promising pediatric dosage form for abdominal pain management. The optimized formulation (DHP6) demonstrated robust physicochemical and performance characteristics, supporting its potential for pediatric use.

Journal of Pharmaceutical InnovationVol. 20(5)
Parul University (IN)
Openalex Percentile: Top 65%
Pharmaceutical studies and practices
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.